Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Substance Withdrawal Clear all
Completed Phase 1 Interventional

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

NCT00829777
View directory record Official record
Conditions
Opiate Addiction
Interventions
6β-Naltrexol escalating doses from 0.05-0.5 mg IV
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

UW Withdraw From Tobacco Study

NCT04969198
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acamprosate to Reduce Symptoms of Alcohol Withdrawal

NCT00106106
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
Interventions
NMR-spectroscopy, Oral acamprosate
Procedure · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers

NCT05335915
View directory record Official record
Conditions
Nicotine Withdrawal, Nicotine Addiction, Drug Effect
Interventions
Nicotine, Cigarette
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

NCT00001008
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders

NCT04556552
View directory record Official record
Conditions
Substance-Related Disorders, Substance Use Disorders, Substance Abuse, Intravenous, Substance Withdrawal, Substance Abuse, Opioid-use Disorder, Opioid Use Disorder, Severe, Opioid Use
Interventions
Non invasive VN stimulation (nVNS), Oxygen (15-O) Water, Sham Stimulation
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jul 22, 2026, 5:55 AM EDT
Completed No phase listed Observational

AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)

NCT04422808
View directory record Official record
Conditions
Withdrawal Syndrome, Iatrogenic Disease
Interventions
Not listed
Lead sponsor
Wilkes University
Other
Eligibility
18 Years and older
Enrollment
2,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

NCT01558934
View directory record Official record
Conditions
Opioid Dependence, Methadone Withdrawal Syndrome
Interventions
Lofexidine HCl
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 22, 2026, 5:55 AM EDT
Completed No phase listed Observational Results available

Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study

NCT00653263
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Withdrawal
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

NCT01740414
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
MN-166 (50 mg) First, Placebo First
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Anxiety During Abstinence in AUD

NCT06793488
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Disulfiram 250 mg, functional MRI
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Acute Withdrawal From Smoked Cocaine - 9

NCT00000292
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance Withdrawal Syndrome, Substance-Related Disorders
Interventions
Cocaine
Procedure
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Carvedilol for Psychostimulant Dependence

NCT01171183
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Withdrawal
Interventions
controlled release carvedilol, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

NCT00661674
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Palonosetron, Hydroxyzine, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Patch for Marijuana Withdrawal

NCT01400243
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Nicotine, Placebo Patch
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Quetiapine on Marijuana Withdrawal and Relapse

NCT00743366
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Marijuana, Quetiapine, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Effects of Ketone Supplementation on Acute Alcohol Withdrawal

NCT06173973
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Withdrawal, Alcohol Dependence, Ketosis
Interventions
Kenetik; Ketone Concentrate, Isocaloric dextrose placebo
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Wernersville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

NCT04759703
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Medications Development for the Treatment of Cannabis Related Disorders

NCT01204723
View directory record Official record
Conditions
Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence, Cannabis Abuse
Interventions
Placebo Aprepitant, Active Aprepitant
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2

NCT00135746
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
nicotine transdermal system
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

NCT00032968
View directory record Official record
Conditions
Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Berkeley, California • Oxnard, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Results available

Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder

NCT05226130
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cervical transcutaneous vagus nerve stimulation (active comparator), Cervical transcutaneous vagus nerve stimulation (sham comparator)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 22, 2026, 5:55 AM EDT